董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Sean E. Brynjelsen | 男 | President, Chief Executive Officer and Director | 48 | 194.64万美元 | 未持股 | 2020-04-15 |
| Paul V. Maier | 男 | Director | 72 | 12.82万美元 | 未持股 | 2020-04-15 |
| Norbert G. Riedel | 男 | Director, Chairman of the Board | 62 | 13.65万美元 | 未持股 | 2020-04-15 |
| Mark L. Baum | 男 | Director | 47 | 11.57万美元 | 未持股 | 2020-04-15 |
| Charles J. Casamento | 男 | Director | 74 | 12.40万美元 | 未持股 | 2020-04-15 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Sean E. Brynjelsen | 男 | President, Chief Executive Officer and Director | 48 | 194.64万美元 | 未持股 | 2020-04-15 |
| W. Wilson Troutman | 男 | Chief Financial Officer, Treasurer, and Secretary | 65 | 86.46万美元 | 未持股 | 2020-04-15 |
董事简历
中英对照 | 中文 | 英文- Sean E. Brynjelsen
-
SeanE.Brynjelsen自2017年6月以来一直担任我们的总裁，首席执行官和董事会成员。在过去的25年里，他在制药行业担任多个高级管理职位。在加入伊顿公学之前，Brynjelsen先生曾担任SagentPharmaceuticals，Inc.公司业务发展部的公司主管和执行Vice President，在那里他进行了一些成功的交易，该公司最终被Nichi-Iko制药有限公司以736毫米的价格收购。任职Sagent公司之前，他曾高级副总裁，Akorn公司的全球业务开发，并执行多种产品和并购交易。他于2016年离开公司时，该公司的市值约为30亿美元，在他任职期间，收入从70毫米增长到超过11亿美元。在职业生涯早期，Brynjelsen曾在百特和辉瑞（Pfizer）（前Hospira）的无菌药品产品开发部门任职数年。Brynjelsen先生也是药物输送和制剂科学领域多项美国专利的指定发明人。Brynjelsen先生在圣母大学（University of Notre Dame）获得工商管理硕士学位，并在伊利诺伊大学（University of Illinois）获得化学理学硕士学位和生物化学理学学士学位。
Sean E. Brynjelsen has served as our President, Chief Executive Officer and a member of our board of directors since June 2017. He has held multiple senior management positions in the pharmaceutical industry over the last 25 years. Prior to joining Eton, Mr. Brynjelsen served as Corporate Officer and Executive Vice President, Business Development, at Sagent Pharmaceuticals, Inc., where he made a number of successful transactions, and the company ultimately was acquired by Nichi-Iko Pharmaceuticals Co., Ltd. for $736MM. Prior to his tenure at Sagent, he was Senior Vice President, Global Business Development for Akorn and executed numerous product and M&A transactions. The company had a market cap of approximately $3 billion when he left the company in 2016 and revenues had increased from $70MM to over $1.1B during his tenure. Earlier in his career, Mr. Brynjelsen spent a number of years in product development focused on sterile pharmaceuticals at both Baxter and Pfizer formerly Hospira. Mr. Brynjelsen is also a named inventor on several U.S. patents in the fields of drug delivery and formulation science. Mr. Brynjelsen earned an MBA degree from the University of Notre Dame and holds a Master of Science in Chemistry and a Bachelor of Science in Biochemistry from the University of Illinois. - SeanE.Brynjelsen自2017年6月以来一直担任我们的总裁，首席执行官和董事会成员。在过去的25年里，他在制药行业担任多个高级管理职位。在加入伊顿公学之前，Brynjelsen先生曾担任SagentPharmaceuticals，Inc.公司业务发展部的公司主管和执行Vice President，在那里他进行了一些成功的交易，该公司最终被Nichi-Iko制药有限公司以736毫米的价格收购。任职Sagent公司之前，他曾高级副总裁，Akorn公司的全球业务开发，并执行多种产品和并购交易。他于2016年离开公司时，该公司的市值约为30亿美元，在他任职期间，收入从70毫米增长到超过11亿美元。在职业生涯早期，Brynjelsen曾在百特和辉瑞（Pfizer）（前Hospira）的无菌药品产品开发部门任职数年。Brynjelsen先生也是药物输送和制剂科学领域多项美国专利的指定发明人。Brynjelsen先生在圣母大学（University of Notre Dame）获得工商管理硕士学位，并在伊利诺伊大学（University of Illinois）获得化学理学硕士学位和生物化学理学学士学位。
- Sean E. Brynjelsen has served as our President, Chief Executive Officer and a member of our board of directors since June 2017. He has held multiple senior management positions in the pharmaceutical industry over the last 25 years. Prior to joining Eton, Mr. Brynjelsen served as Corporate Officer and Executive Vice President, Business Development, at Sagent Pharmaceuticals, Inc., where he made a number of successful transactions, and the company ultimately was acquired by Nichi-Iko Pharmaceuticals Co., Ltd. for $736MM. Prior to his tenure at Sagent, he was Senior Vice President, Global Business Development for Akorn and executed numerous product and M&A transactions. The company had a market cap of approximately $3 billion when he left the company in 2016 and revenues had increased from $70MM to over $1.1B during his tenure. Earlier in his career, Mr. Brynjelsen spent a number of years in product development focused on sterile pharmaceuticals at both Baxter and Pfizer formerly Hospira. Mr. Brynjelsen is also a named inventor on several U.S. patents in the fields of drug delivery and formulation science. Mr. Brynjelsen earned an MBA degree from the University of Notre Dame and holds a Master of Science in Chemistry and a Bachelor of Science in Biochemistry from the University of Illinois.
- Paul V. Maier
-
Paul V. Maier， 他拥有工商管理硕士学位。2009年11月以来，他一直担任我们的首席财务官。他曾担任Ligand Pharmaceuticals Incorporated公司的高级副总裁兼首席财务官，在那里他帮助Ligand公司从一个商业风险阶段公司转变为一个集成生物制药的组织（从1992年到2007年1月）。任职Ligand公司之前，他曾任职ICN Pharmaceuticals公司6年，担任多种管理和财务职务。他目前担任International Stem Cell Corporation和Apricus Biosciences公司的董事。他持有哈佛大学（Harvard University）的工商管理硕士学位。
Paul V. Maier has served as a member of our board of directors since September 2017. Mr. Maier has over 25 years of experience as a senior executive in biotechnology and pharmaceutical companies and more than 15 years of experience as a director of multiple life science public and private company Boards. In addition to his Board positions, Mr. Maier also currently serves as an advisor to the life science industry. In June 2014 Mr. Maier retired after serving since November 2009 as Chief Financial Officer of Sequenom, Inc., a publicly held company serving the discovery, clinical research, and molecular diagnostics market. From February 2007 until November 2009 Mr. Maier served as an independent financial consultant. Previously, Mr. Maier was Senior Vice President and Chief Financial Officer of Ligand Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, a position he held from 1992 to 2007. From 1990 to 1992 Mr. Maier served as Vice President, Finance of DFW West, a division of DFS Group, LP a private multinational retailer. From 1984 to 1990 Mr. Maier was employed by ICN Pharmaceuticals, a pharmaceutical and biotechnology research products company, where he held various executive positions in finance and general management in ICN as well as SPI Pharmaceuticals, a publicly held subsidiary. Mr. Maier currently serves on the Board of Directors of International Stem Cell Corporation, Biological Dynamics, and Ritter Pharmaceuticals. He also serves as Vice Chairman of the Board of Lackey Clinic, a non-profit providing healthcare to those without insurance. Mr. Maier received an MBA from Harvard Business School and a BS from Pennsylvania State University. Mr. Maier is currently an Executive Partner at The College of William and Mary’s Mason School of Business. - Paul V. Maier， 他拥有工商管理硕士学位。2009年11月以来，他一直担任我们的首席财务官。他曾担任Ligand Pharmaceuticals Incorporated公司的高级副总裁兼首席财务官，在那里他帮助Ligand公司从一个商业风险阶段公司转变为一个集成生物制药的组织（从1992年到2007年1月）。任职Ligand公司之前，他曾任职ICN Pharmaceuticals公司6年，担任多种管理和财务职务。他目前担任International Stem Cell Corporation和Apricus Biosciences公司的董事。他持有哈佛大学（Harvard University）的工商管理硕士学位。
- Paul V. Maier has served as a member of our board of directors since September 2017. Mr. Maier has over 25 years of experience as a senior executive in biotechnology and pharmaceutical companies and more than 15 years of experience as a director of multiple life science public and private company Boards. In addition to his Board positions, Mr. Maier also currently serves as an advisor to the life science industry. In June 2014 Mr. Maier retired after serving since November 2009 as Chief Financial Officer of Sequenom, Inc., a publicly held company serving the discovery, clinical research, and molecular diagnostics market. From February 2007 until November 2009 Mr. Maier served as an independent financial consultant. Previously, Mr. Maier was Senior Vice President and Chief Financial Officer of Ligand Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, a position he held from 1992 to 2007. From 1990 to 1992 Mr. Maier served as Vice President, Finance of DFW West, a division of DFS Group, LP a private multinational retailer. From 1984 to 1990 Mr. Maier was employed by ICN Pharmaceuticals, a pharmaceutical and biotechnology research products company, where he held various executive positions in finance and general management in ICN as well as SPI Pharmaceuticals, a publicly held subsidiary. Mr. Maier currently serves on the Board of Directors of International Stem Cell Corporation, Biological Dynamics, and Ritter Pharmaceuticals. He also serves as Vice Chairman of the Board of Lackey Clinic, a non-profit providing healthcare to those without insurance. Mr. Maier received an MBA from Harvard Business School and a BS from Pennsylvania State University. Mr. Maier is currently an Executive Partner at The College of William and Mary’s Mason School of Business.
- Norbert G. Riedel
-
Norbert G. Riedel博士是Naurex公司的总裁兼首席执行官，Naurex公司是一家临床生物制药公司，专注于开发治疗难治性抑郁以及罕见病和其他具有挑战性的中枢神经系统疾病的药物。 2014年1月加入Naurex之前，即2001年3月到2013年1月，他是Baxter International（一家多元化的医疗保健公司）的副总裁和研发主任。2013年1月至2014年1月，他曾在Eton Pharmaceuticals, Inc.和一下提到的公司里担任董事。1998年到2001年，他在Baxter的重组治疗性蛋白质研制部和研发部担任总裁和总经理。加入Baxter之前，从1996年到1998年，他在Hoechst-Marion Roussel现在为Sanofi-Aventis公司（一家全球制药公司）担任全球生物技术和全球核心研究所的高管。此前，他还在 Hoechst-Marion Roussel 和 Hoechst AG担任了一系列的科学管理职位。2013年5月以来，他还是Jazz Pharmaceuticals 公司的董事会成员；2003年到2013年，他在MediGene AG（一家生物技术公司）的监事会成员。他是Illinois Biotechnology Industry Organization 的董事会成员，也是代凯洛格管理学院和麦考密克工程学的生物技术中心咨询委员会成员。最近，他被任命为由伊利诺伊州州长帕特·奎恩新成立的伊利诺斯州创新委员会成员。1999年到2010年，他在Oscient制药公司担任董事会成员。1984年到1987年，他是哈佛大学的博士后研究员；1987年到1991年，他是波士顿大学医学院的助理教授；波士顿大学医学院兼职教授，西北大学的医学副教授；1992年担任麻省理工学院的医学院客座教授。并在2009年当选为奥地利科学学院的成员。1981年他取得了法兰克福大学的生物化学学士，1983取得了法兰克福大学的生物化学博士学位。
Norbert G. Riedel,has served as a member of Jazz Pharmaceuticals Public Limited Company board of directors since May 2013 and was appointed chair of Jazz Pharmaceuticals Public Limited Company science and medicine committee in April 2022. Dr. Riedel currently serves on the boards of directors of two other publicly-held companies, Eton Pharmaceuticals, Inc., a development stage pharmaceutical company, where he serves as Chairperson of the board, and Cerevel Therapeutics Holdings, Inc., a biopharmaceutical company, where he serves as Lead Independent Director. Dr. Riedel also currently serves on the board of directors of a non-profit organization, the Illinois Biotechnology Industry Organization, and is a member of the Austrian Academy of Sciences. Dr. Riedel is an Adjunct Professor at Boston University School of Medicine and an Adjunct Professor of Medicine at Northwestern University's Feinberg School of Medicine. Dr. Riedel served as Executive Chairperson of Aptinyx Inc. from January 2022 to May 2023, as Chief Executive Officer from September 2015 to December 2021 and as President from September 2015 to December 2020. Aptinyx Inc. is a biopharmaceutical company spun out of its predecessor company, Naurex, Inc., where Dr. Riedel served as Chief Executive Officer and President from January 2014 to September 2015. From 2001 to 2013, he served as Corporate Vice President and Chief Scientific Officer of Baxter International Inc., a diversified healthcare company, where from 1998 to 2001, he also served as President and General Manager of the recombinant therapeutic proteins business unit and Vice President of Research and Development of the bioscience business unit. From 1996 to 1998, Dr. Riedel served as head of worldwide biotechnology and worldwide core research functions at Hoechst-Marion Roussel, now Sanofi, a global pharmaceutical company. Dr. Riedel served on the board of directors of Ariad Pharmaceuticals, Inc., an oncology company, from May 2011 until the company was acquired in February 2017. Dr. Riedel holds a Diploma in biochemistry and a Ph.D. in biochemistry from the University of Frankfurt. - Norbert G. Riedel博士是Naurex公司的总裁兼首席执行官，Naurex公司是一家临床生物制药公司，专注于开发治疗难治性抑郁以及罕见病和其他具有挑战性的中枢神经系统疾病的药物。 2014年1月加入Naurex之前，即2001年3月到2013年1月，他是Baxter International（一家多元化的医疗保健公司）的副总裁和研发主任。2013年1月至2014年1月，他曾在Eton Pharmaceuticals, Inc.和一下提到的公司里担任董事。1998年到2001年，他在Baxter的重组治疗性蛋白质研制部和研发部担任总裁和总经理。加入Baxter之前，从1996年到1998年，他在Hoechst-Marion Roussel现在为Sanofi-Aventis公司（一家全球制药公司）担任全球生物技术和全球核心研究所的高管。此前，他还在 Hoechst-Marion Roussel 和 Hoechst AG担任了一系列的科学管理职位。2013年5月以来，他还是Jazz Pharmaceuticals 公司的董事会成员；2003年到2013年，他在MediGene AG（一家生物技术公司）的监事会成员。他是Illinois Biotechnology Industry Organization 的董事会成员，也是代凯洛格管理学院和麦考密克工程学的生物技术中心咨询委员会成员。最近，他被任命为由伊利诺伊州州长帕特·奎恩新成立的伊利诺斯州创新委员会成员。1999年到2010年，他在Oscient制药公司担任董事会成员。1984年到1987年，他是哈佛大学的博士后研究员；1987年到1991年，他是波士顿大学医学院的助理教授；波士顿大学医学院兼职教授，西北大学的医学副教授；1992年担任麻省理工学院的医学院客座教授。并在2009年当选为奥地利科学学院的成员。1981年他取得了法兰克福大学的生物化学学士，1983取得了法兰克福大学的生物化学博士学位。
- Norbert G. Riedel,has served as a member of Jazz Pharmaceuticals Public Limited Company board of directors since May 2013 and was appointed chair of Jazz Pharmaceuticals Public Limited Company science and medicine committee in April 2022. Dr. Riedel currently serves on the boards of directors of two other publicly-held companies, Eton Pharmaceuticals, Inc., a development stage pharmaceutical company, where he serves as Chairperson of the board, and Cerevel Therapeutics Holdings, Inc., a biopharmaceutical company, where he serves as Lead Independent Director. Dr. Riedel also currently serves on the board of directors of a non-profit organization, the Illinois Biotechnology Industry Organization, and is a member of the Austrian Academy of Sciences. Dr. Riedel is an Adjunct Professor at Boston University School of Medicine and an Adjunct Professor of Medicine at Northwestern University's Feinberg School of Medicine. Dr. Riedel served as Executive Chairperson of Aptinyx Inc. from January 2022 to May 2023, as Chief Executive Officer from September 2015 to December 2021 and as President from September 2015 to December 2020. Aptinyx Inc. is a biopharmaceutical company spun out of its predecessor company, Naurex, Inc., where Dr. Riedel served as Chief Executive Officer and President from January 2014 to September 2015. From 2001 to 2013, he served as Corporate Vice President and Chief Scientific Officer of Baxter International Inc., a diversified healthcare company, where from 1998 to 2001, he also served as President and General Manager of the recombinant therapeutic proteins business unit and Vice President of Research and Development of the bioscience business unit. From 1996 to 1998, Dr. Riedel served as head of worldwide biotechnology and worldwide core research functions at Hoechst-Marion Roussel, now Sanofi, a global pharmaceutical company. Dr. Riedel served on the board of directors of Ariad Pharmaceuticals, Inc., an oncology company, from May 2011 until the company was acquired in February 2017. Dr. Riedel holds a Diploma in biochemistry and a Ph.D. in biochemistry from the University of Frankfurt.
- Mark L. Baum
-
Mark L. Baum，自2011年12月起，担任董事；2011年12月16日至2012年4月1日，他担任本公司董事长。2011年12月起，他还担任本公司主要执行官；2012年4月1日，正式被任命为首席执行官。1998年起，他曾是 The Baum Law Firm, P.C。 （现 TBLF, LLC）的负责人，在小市值上市企业的融资、经营及咨询业务，尤其是重组业务方面，有着超过15年的经验。作为一名资本经理，他已经为40多家公司完成了超过125轮融资。作为一名证券法律师，他专注于涉及小市值上市公司相关的美国证券法、报告要求和上市公司财务的事务。他广泛的参与过众多上市公司的分拆、业务重组与资本重组、风险投资、私营到上市的兼并、资产收购和资产剥离等业务。除了资金管理和法律经验，他在以下行业也有运作经验：制药、医疗诊断、封闭型药房、清洁和可再生能源、零售家居摆设。他目前担任：Ideal Power, Inc. （www.idealpower.com，纳斯达克代码： IPWR）的董事会成员、审核委员会主席；Endra, Inc.（www.endrainc.com）的董事长，位于密歇根州Ann Arbor的私营公司。他曾是多家公司的董事会成员，包括：Chembio Diagnostic Systems, Inc.、Applied Natural Gas Fuels, Inc.、Shrink Nanotechnologies, Inc.、You on Demand, Inc.，和 CoConnect, Inc.。他是发表发明者，也是the State Bar of California 和 the State Bar of Texas的刊发创始人和非执业成员。他为本公司董事会带来了多年的上市公司管理经验，以及证券法、报告要求和上市公司财务相关问题的丰富知识。
Mark L. Baum has served as a member of our board of directors since our inception in April 2017. Mr. Baum is a founder, member of the board of directors and Chief Executive Officer of Harrow Health, Inc., formerly known as Imprimis Pharmaceuticals, Inc. “Harrow”, is the founder and a member of the board of directors of Surface Pharmaceuticals, Inc., and is a founder and member of the board of directors of Melt Pharmaceuticals, Inc. Prior to Mr. Baum’s involvement with Harrow, from 2001 to 2011 he was the founder and managing director of TBLF, LLC, a consulting firm and fund manager, where he managed a series of three funds and acted as a principal investor in financing publicly traded companies or bridge-to-public equity transactions. Before his fund management experience, Mr. Baum founded and served as the president of YesRx, and practiced as a U.S. securities lawyer focused on public company reporting requirements and finance-related matters. Mr. Baum also served on the board of directors for Ideal Power, Inc. until December 31 2017 where he was chairman of the audit committee. In 2017 Mr. Baum was named Entrepreneur of the Year™ for the San Diego region life sciences category by Ernst & Young LLP. Mr. Baum is a graduate, cum laude, of the University of Texas at Arlington and a graduate of California Western School of Law. - Mark L. Baum，自2011年12月起，担任董事；2011年12月16日至2012年4月1日，他担任本公司董事长。2011年12月起，他还担任本公司主要执行官；2012年4月1日，正式被任命为首席执行官。1998年起，他曾是 The Baum Law Firm, P.C。 （现 TBLF, LLC）的负责人，在小市值上市企业的融资、经营及咨询业务，尤其是重组业务方面，有着超过15年的经验。作为一名资本经理，他已经为40多家公司完成了超过125轮融资。作为一名证券法律师，他专注于涉及小市值上市公司相关的美国证券法、报告要求和上市公司财务的事务。他广泛的参与过众多上市公司的分拆、业务重组与资本重组、风险投资、私营到上市的兼并、资产收购和资产剥离等业务。除了资金管理和法律经验，他在以下行业也有运作经验：制药、医疗诊断、封闭型药房、清洁和可再生能源、零售家居摆设。他目前担任：Ideal Power, Inc. （www.idealpower.com，纳斯达克代码： IPWR）的董事会成员、审核委员会主席；Endra, Inc.（www.endrainc.com）的董事长，位于密歇根州Ann Arbor的私营公司。他曾是多家公司的董事会成员，包括：Chembio Diagnostic Systems, Inc.、Applied Natural Gas Fuels, Inc.、Shrink Nanotechnologies, Inc.、You on Demand, Inc.，和 CoConnect, Inc.。他是发表发明者，也是the State Bar of California 和 the State Bar of Texas的刊发创始人和非执业成员。他为本公司董事会带来了多年的上市公司管理经验，以及证券法、报告要求和上市公司财务相关问题的丰富知识。
- Mark L. Baum has served as a member of our board of directors since our inception in April 2017. Mr. Baum is a founder, member of the board of directors and Chief Executive Officer of Harrow Health, Inc., formerly known as Imprimis Pharmaceuticals, Inc. “Harrow”, is the founder and a member of the board of directors of Surface Pharmaceuticals, Inc., and is a founder and member of the board of directors of Melt Pharmaceuticals, Inc. Prior to Mr. Baum’s involvement with Harrow, from 2001 to 2011 he was the founder and managing director of TBLF, LLC, a consulting firm and fund manager, where he managed a series of three funds and acted as a principal investor in financing publicly traded companies or bridge-to-public equity transactions. Before his fund management experience, Mr. Baum founded and served as the president of YesRx, and practiced as a U.S. securities lawyer focused on public company reporting requirements and finance-related matters. Mr. Baum also served on the board of directors for Ideal Power, Inc. until December 31 2017 where he was chairman of the audit committee. In 2017 Mr. Baum was named Entrepreneur of the Year™ for the San Diego region life sciences category by Ernst & Young LLP. Mr. Baum is a graduate, cum laude, of the University of Texas at Arlington and a graduate of California Western School of Law.
- Charles J. Casamento
-
Charles J. Casamento，于2017年3月被任命为董事会成员。2007年以来，Casamento先生一直担任The Sage Group（一家医疗保健咨询集团）的执行董事和负责人。此前，从2004年10月到2007年4月，他担任Osteologix（一家初创公司，他监督上市）的总裁兼首席执行官。从1999年到2004年，他是Questcor Pharmaceuticals的创始人，担任总裁、首席执行官和主席。在他任职Questcor期间，公司收购了Acthar，这款产品的销售额最终超过了10亿美元。他也曾担任RiboGene Inc.的总裁、首席执行官和主席，直到1999年RiboGene与另一家公司合并形成Questcor。他也是Indevus（前身为Interneuron Pharmaceuticals）的联合创始人、总裁兼首席执行官，并在Genzyme Corporation担任高级管理职位，在那里他曾担任美国医院供应高级副总裁，在那里他曾担任重症护理部门、Johnson & Johnson、hoffman - laroche和Sandoz的业务发展副总裁。他目前担任Relmada Therapeutics （OTCQB： RLMD）的董事会主席，Eton Pharmaceuticals （Nasdaq： Eton）的董事会成员，PaxMedica, Inc. （Nasdaq： PXMD）的董事会成员，此前担任Catholic Medical Missions Board（大型非营利性国际组织）的董事和副主席。他持有Fordham University的药学学士学位和Iona College的工商管理硕士学位。
Charles J. Casamento,was appointed to Gt Biopharma, Inc. Board of Directors on May 1, 2023. Mr. Casamento is currently executive director and principal of The Sage Group, a healthcare advisory group specializing in mergers, acquisitions, and partnerships between biotechnology companies and pharmaceutical companies, since 2007. He was the president and CEO of Osteologix, Inc., a public biopharmaceutical company developing products for treating osteoporosis, from 2004 through 2007. Mr. Casamento was founder of, and from 1999 through 2004, served as chairman of the board, president and CEO, of Questcor Pharmaceuticals, Inc. which was subsequently acquired by Mallinckrodt. Mr. Casamento formerly served as RiboGene, Inc.'s president, CEO and chairman of the board from 1993 through 1999 until it merged with Cypros to form Questcor. He was co-founder, president and CEO of Interneuron Pharmaceuticals, Inc. (Indevus), a biopharmaceutical company, from 1989 until 1993. Indevus was eventually acquired by Endo. Mr. Casamento has also held senior management positions at Genzyme Corporation, where he was senior vice president, pharmaceuticals and biochemicals; American Hospital Supply, where he was vice president of business development and strategic planning for the Critical Care Division; Johnson & Johnson, Hoffmann-LaRoche, Inc. and Sandoz Inc. (now Novartis). Mr. Casamento also serves on the board of directors of Eton Pharmaceuticals, Inc. (Nasdaq: ETON), First Wave Biopharma, Inc. (Nasdaq: FWBI) and Relmada Therapeutics, Inc. (Nasdaq: RLMD). During his career he has served on the boards of fourteen Biotech/Pharma companies and has also been a director and vice chairman of The Catholic Medical Missions Board, a large not-for-profit organization providing health care services to third world countries. He has served as a guest lecturer at Fordham University and is on the Science Council of Fordham University. He holds a bachelor's degree in Pharmacy from Fordham University and an MBA from Iona University and was originally licensed to practice pharmacy in the states of New York and New Jersey. - Charles J. Casamento，于2017年3月被任命为董事会成员。2007年以来，Casamento先生一直担任The Sage Group（一家医疗保健咨询集团）的执行董事和负责人。此前，从2004年10月到2007年4月，他担任Osteologix（一家初创公司，他监督上市）的总裁兼首席执行官。从1999年到2004年，他是Questcor Pharmaceuticals的创始人，担任总裁、首席执行官和主席。在他任职Questcor期间，公司收购了Acthar，这款产品的销售额最终超过了10亿美元。他也曾担任RiboGene Inc.的总裁、首席执行官和主席，直到1999年RiboGene与另一家公司合并形成Questcor。他也是Indevus（前身为Interneuron Pharmaceuticals）的联合创始人、总裁兼首席执行官，并在Genzyme Corporation担任高级管理职位，在那里他曾担任美国医院供应高级副总裁，在那里他曾担任重症护理部门、Johnson & Johnson、hoffman - laroche和Sandoz的业务发展副总裁。他目前担任Relmada Therapeutics （OTCQB： RLMD）的董事会主席，Eton Pharmaceuticals （Nasdaq： Eton）的董事会成员，PaxMedica, Inc. （Nasdaq： PXMD）的董事会成员，此前担任Catholic Medical Missions Board（大型非营利性国际组织）的董事和副主席。他持有Fordham University的药学学士学位和Iona College的工商管理硕士学位。
- Charles J. Casamento,was appointed to Gt Biopharma, Inc. Board of Directors on May 1, 2023. Mr. Casamento is currently executive director and principal of The Sage Group, a healthcare advisory group specializing in mergers, acquisitions, and partnerships between biotechnology companies and pharmaceutical companies, since 2007. He was the president and CEO of Osteologix, Inc., a public biopharmaceutical company developing products for treating osteoporosis, from 2004 through 2007. Mr. Casamento was founder of, and from 1999 through 2004, served as chairman of the board, president and CEO, of Questcor Pharmaceuticals, Inc. which was subsequently acquired by Mallinckrodt. Mr. Casamento formerly served as RiboGene, Inc.'s president, CEO and chairman of the board from 1993 through 1999 until it merged with Cypros to form Questcor. He was co-founder, president and CEO of Interneuron Pharmaceuticals, Inc. (Indevus), a biopharmaceutical company, from 1989 until 1993. Indevus was eventually acquired by Endo. Mr. Casamento has also held senior management positions at Genzyme Corporation, where he was senior vice president, pharmaceuticals and biochemicals; American Hospital Supply, where he was vice president of business development and strategic planning for the Critical Care Division; Johnson & Johnson, Hoffmann-LaRoche, Inc. and Sandoz Inc. (now Novartis). Mr. Casamento also serves on the board of directors of Eton Pharmaceuticals, Inc. (Nasdaq: ETON), First Wave Biopharma, Inc. (Nasdaq: FWBI) and Relmada Therapeutics, Inc. (Nasdaq: RLMD). During his career he has served on the boards of fourteen Biotech/Pharma companies and has also been a director and vice chairman of The Catholic Medical Missions Board, a large not-for-profit organization providing health care services to third world countries. He has served as a guest lecturer at Fordham University and is on the Science Council of Fordham University. He holds a bachelor's degree in Pharmacy from Fordham University and an MBA from Iona University and was originally licensed to practice pharmacy in the states of New York and New Jersey.
高管简历
中英对照 | 中文 | 英文- Sean E. Brynjelsen
SeanE.Brynjelsen自2017年6月以来一直担任我们的总裁，首席执行官和董事会成员。在过去的25年里，他在制药行业担任多个高级管理职位。在加入伊顿公学之前，Brynjelsen先生曾担任SagentPharmaceuticals，Inc.公司业务发展部的公司主管和执行Vice President，在那里他进行了一些成功的交易，该公司最终被Nichi-Iko制药有限公司以736毫米的价格收购。任职Sagent公司之前，他曾高级副总裁，Akorn公司的全球业务开发，并执行多种产品和并购交易。他于2016年离开公司时，该公司的市值约为30亿美元，在他任职期间，收入从70毫米增长到超过11亿美元。在职业生涯早期，Brynjelsen曾在百特和辉瑞（Pfizer）（前Hospira）的无菌药品产品开发部门任职数年。Brynjelsen先生也是药物输送和制剂科学领域多项美国专利的指定发明人。Brynjelsen先生在圣母大学（University of Notre Dame）获得工商管理硕士学位，并在伊利诺伊大学（University of Illinois）获得化学理学硕士学位和生物化学理学学士学位。
Sean E. Brynjelsen has served as our President, Chief Executive Officer and a member of our board of directors since June 2017. He has held multiple senior management positions in the pharmaceutical industry over the last 25 years. Prior to joining Eton, Mr. Brynjelsen served as Corporate Officer and Executive Vice President, Business Development, at Sagent Pharmaceuticals, Inc., where he made a number of successful transactions, and the company ultimately was acquired by Nichi-Iko Pharmaceuticals Co., Ltd. for $736MM. Prior to his tenure at Sagent, he was Senior Vice President, Global Business Development for Akorn and executed numerous product and M&A transactions. The company had a market cap of approximately $3 billion when he left the company in 2016 and revenues had increased from $70MM to over $1.1B during his tenure. Earlier in his career, Mr. Brynjelsen spent a number of years in product development focused on sterile pharmaceuticals at both Baxter and Pfizer formerly Hospira. Mr. Brynjelsen is also a named inventor on several U.S. patents in the fields of drug delivery and formulation science. Mr. Brynjelsen earned an MBA degree from the University of Notre Dame and holds a Master of Science in Chemistry and a Bachelor of Science in Biochemistry from the University of Illinois.- SeanE.Brynjelsen自2017年6月以来一直担任我们的总裁，首席执行官和董事会成员。在过去的25年里，他在制药行业担任多个高级管理职位。在加入伊顿公学之前，Brynjelsen先生曾担任SagentPharmaceuticals，Inc.公司业务发展部的公司主管和执行Vice President，在那里他进行了一些成功的交易，该公司最终被Nichi-Iko制药有限公司以736毫米的价格收购。任职Sagent公司之前，他曾高级副总裁，Akorn公司的全球业务开发，并执行多种产品和并购交易。他于2016年离开公司时，该公司的市值约为30亿美元，在他任职期间，收入从70毫米增长到超过11亿美元。在职业生涯早期，Brynjelsen曾在百特和辉瑞（Pfizer）（前Hospira）的无菌药品产品开发部门任职数年。Brynjelsen先生也是药物输送和制剂科学领域多项美国专利的指定发明人。Brynjelsen先生在圣母大学（University of Notre Dame）获得工商管理硕士学位，并在伊利诺伊大学（University of Illinois）获得化学理学硕士学位和生物化学理学学士学位。
- Sean E. Brynjelsen has served as our President, Chief Executive Officer and a member of our board of directors since June 2017. He has held multiple senior management positions in the pharmaceutical industry over the last 25 years. Prior to joining Eton, Mr. Brynjelsen served as Corporate Officer and Executive Vice President, Business Development, at Sagent Pharmaceuticals, Inc., where he made a number of successful transactions, and the company ultimately was acquired by Nichi-Iko Pharmaceuticals Co., Ltd. for $736MM. Prior to his tenure at Sagent, he was Senior Vice President, Global Business Development for Akorn and executed numerous product and M&A transactions. The company had a market cap of approximately $3 billion when he left the company in 2016 and revenues had increased from $70MM to over $1.1B during his tenure. Earlier in his career, Mr. Brynjelsen spent a number of years in product development focused on sterile pharmaceuticals at both Baxter and Pfizer formerly Hospira. Mr. Brynjelsen is also a named inventor on several U.S. patents in the fields of drug delivery and formulation science. Mr. Brynjelsen earned an MBA degree from the University of Notre Dame and holds a Master of Science in Chemistry and a Bachelor of Science in Biochemistry from the University of Illinois.
- W. Wilson Troutman
W.Wilson Troutman自2017年7月起担任我们的首席财务官，财务主管和秘书。从2012年到加入Century Aluminum公司，他曾担任Omeda Communications公司的Vice President兼首席财务官，在此之前，他曾担任Akorn，Inc.公司（仿制药产品的制造商和分销商）的公司总会计师兼财务主管（2004年至2012年）。Troutman先生于1987年在芝加哥大学（University of Chicago）获得工商管理硕士学位，并于1976年在伊利诺伊大学厄巴纳分校（University of Illinois-Urbana）获得学士学位。他于1977年成为注册会计师，是the AICPA、the Illinois CPA Society和Financial Executives International的成员。
W. Wilson Troutman has served as our Chief Financial Officer, Treasurer and Secretary since July 2017.From 2012 until joining Century Aluminum, he served as Vice President and Chief Financial Officer for Omeda Communications, and prior to that he was the Corporate Controller and Treasurer for Akorn, Inc., a manufacturer and distributor of generic pharmaceutical products from 2004 to 2012. Mr. Troutman received an MBA from the University of Chicago in 1987 and a BS from the University of Illinois-Urbana in 1976. He became a Certified Public Accountant in 1977 and is a member of the AICPA, the Illinois CPA Society and Financial Executives International.- W.Wilson Troutman自2017年7月起担任我们的首席财务官，财务主管和秘书。从2012年到加入Century Aluminum公司，他曾担任Omeda Communications公司的Vice President兼首席财务官，在此之前，他曾担任Akorn，Inc.公司（仿制药产品的制造商和分销商）的公司总会计师兼财务主管（2004年至2012年）。Troutman先生于1987年在芝加哥大学（University of Chicago）获得工商管理硕士学位，并于1976年在伊利诺伊大学厄巴纳分校（University of Illinois-Urbana）获得学士学位。他于1977年成为注册会计师，是the AICPA、the Illinois CPA Society和Financial Executives International的成员。
- W. Wilson Troutman has served as our Chief Financial Officer, Treasurer and Secretary since July 2017.From 2012 until joining Century Aluminum, he served as Vice President and Chief Financial Officer for Omeda Communications, and prior to that he was the Corporate Controller and Treasurer for Akorn, Inc., a manufacturer and distributor of generic pharmaceutical products from 2004 to 2012. Mr. Troutman received an MBA from the University of Chicago in 1987 and a BS from the University of Illinois-Urbana in 1976. He became a Certified Public Accountant in 1977 and is a member of the AICPA, the Illinois CPA Society and Financial Executives International.